Why Are Only 30% of Veterans Receiving Medication for Alcohol Use Disorder?

By VirentaNews Staff — May 15, 2026

Why are so few Veterans receiving medication for alcohol use disorder (AUD) after hospitalization, even when they’re already under medical care? Despite decades of research supporting the effectiveness of medications for alcohol use disorder (MAUD), a startlingly low proportion of Veterans are being prescribed these treatments. A recent study published in the Annals of Internal Medicine found that only 30% of Veterans hospitalized for AUD within the Veterans Health Administration (VHA) received MAUD either during their inpatient stay or within seven days of discharge. This raises urgent questions about treatment gaps in one of the nation’s largest healthcare systems—and whether systemic, cultural, or clinical barriers are preventing life-saving interventions from reaching those who need them most.

How Common Is Medication Initiation After AUD Hospitalization?

The study analyzed data from over 8,000 Veterans who were hospitalized for alcohol use disorder across the VHA between 2015 and 2022. Researchers found that just 30% began treatment with FDA-approved medications such as naltrexone, acamprosate, or disulfiram during hospitalization or within one week of discharge. These medications, when combined with behavioral therapies, have been shown to reduce relapse rates, decrease heavy drinking days, and improve long-term recovery outcomes. Despite clear clinical guidelines from the Department of Veterans Affairs and external bodies like the American Society of Addiction Medicine, initiation of MAUD remains inconsistent. The findings suggest that even within a highly integrated healthcare system like the VHA, evidence-based practices are not being uniformly adopted—especially during critical windows like hospitalization, when patients may be most receptive to treatment.

What Does the Evidence Say About Medication Effectiveness?

Multiple clinical trials and meta-analyses confirm that medications for AUD are effective. A 2022 Cochrane review found that naltrexone reduces the risk of returning to heavy drinking by about 17%, while acamprosate increases the likelihood of maintaining abstinence. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) emphasizes that pharmacological treatment should be a standard component of AUD care. Yet, the VHA study highlights a major implementation gap. Researchers noted that younger Veterans, those with co-occurring mental health conditions, and individuals with a history of prior AUD treatment were more likely to receive MAUD—suggesting that clinicians may be reserving medication for higher-risk or more engaged patients. However, this selective approach may overlook others who could benefit. Internal VHA directives since 2020 have encouraged routine screening and proactive medication initiation, but local practices vary widely across facilities.

Are There Valid Reasons for Low Medication Uptake?

Some clinicians argue that initiating medication during or immediately after hospitalization may not be appropriate for all patients. Concerns include lack of patient readiness, potential side effects, and the complexity of managing polypharmacy in a population with high rates of comorbid PTSD, depression, and chronic pain. Additionally, some providers adhere to abstinence-based models that prioritize psychosocial interventions over pharmacotherapy. Cultural stigma around using medications to treat addiction—viewed by some as replacing one substance with another—persists in both clinical and veteran communities. There are also structural barriers: limited training in addiction medicine among non-specialist providers, fragmented care transitions, and lack of follow-up systems to ensure continuity. While these factors may partially explain the 30% figure, they do not justify the persistent underuse of treatments with strong empirical support.

What Are the Real-World Consequences of This Treatment Gap?

The consequences of missing this treatment window are profound. Veterans with AUD face elevated risks of liver disease, suicide, homelessness, and unemployment. Hospitalization often follows a crisis—such as withdrawal, injury, or psychiatric decompensation—making it a pivotal moment for intervention. When MAUD is not initiated during this window, relapse rates climb. Studies show that untreated AUD leads to higher readmission rates, increased emergency department use, and greater long-term healthcare costs. A 2021 VA report found that Veterans with substance use disorders are twice as likely to die by suicide compared to those without. By failing to act during hospitalization, the system may be missing its best chance to alter trajectories. Facilities that have implemented standardized MAUD protocols, such as the VA Puget Sound Health Care System, report initiation rates above 60%, proving that change is possible with dedicated resources and provider education.

What This Means For You

If you or a loved one is a Veteran navigating AUD, this study underscores the importance of advocating for comprehensive treatment—including medication. Not all providers will bring up MAUD automatically, so asking about FDA-approved options like naltrexone or acamprosate could make a critical difference. Recovery is most effective when medication and counseling are combined. Families and caregivers should know that MAUD is not a substitute for willpower—it’s a medical tool that stabilizes brain chemistry and supports sustained sobriety. The VA has resources, but access depends on informed patients and proactive care teams.

Given the proven benefits of medication and the high stakes involved, why does a majority of Veterans still leave the hospital without it? And what systemic changes—such as mandatory provider training, performance metrics, or integrated care pathways—could close this gap across all VA facilities? The answer may lie not in discovering new treatments, but in delivering existing ones more equitably.

Source: MedicalXpress